drugset
drugset / Trial / NCT04896112

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

NCT04896112 ↗

Phase 1 Withdrawn Lynk Pharmaceuticals Co., Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (PMF), or MF due to polycythemia vera (PV-MF), or essential thrombocythemia (ET-MF), polycythemia vera (PV), or with acute myeloid leukemia (AML).

Timeline

Start
2021-04-08
Primary completion
2022-10-20
Completion
2022-10-20

Outcome

Outcome not reported

Stopped (Business): “sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject LNK01002 Unknown 15 mg Oral
Subject LNK01002 Unknown 30 mg Oral
Subject LNK01002 Unknown 60 mg Oral
Subject LNK01002 Unknown 100 mg Oral
Subject LNK01002 Unknown 150 mg Oral
Subject LNK01002 Unknown 200 mg Oral
Subject LNK01002 Unknown 260 mg Oral

Indications

acquired polycythemia vera acute myeloid leukemia myelofibrosis primary myelofibrosis